Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease

Movement Disorders

Volumn 26, Issue 14, 2011, Pages 2504-2508

  Espay, Alberto J ^a   Giuffrida, Joe P ^b   Chen, Robert ^c   Payne, Megan ^a   Mazzella, Filomena ^c   Dunn, Emily ^a   Vaughan, Jennifer E ^a   Duker, Andrew P ^a   Sahay, Alok ^a   Kim, Sang Jin ^c   Revilla, Fredy J ^a   Heldman, Dustin A ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Great Lakes NeuroTechnologies Inc   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bradykinesia; KinetiSense; MBRS; Parkinson's disease; UPDRS

Indexed keywords

ANTIPARKINSON AGENT;

ADULT; AGED; AMPLITUDE MODULATION; ARTICLE; BODY POSTURE; BRADYKINESIA; DYSRHYTHMIA; FATIGUE; GRIP STRENGTH; HUMAN; HYPOKINESIA; KINEMATICS; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; RHYTHM; SCORING SYSTEM; TASK PERFORMANCE; TREATMENT RESPONSE; VELOCITY;

AGED; AGED, 80 AND OVER; DOPAMINE AGENTS; DRUG MONITORING; HUMANS; HYPOKINESIA; LEVODOPA; MIDDLE AGED; MOVEMENT; NEUROLOGIC EXAMINATION; NEUROLOGY; OBSERVER VARIATION; PARKINSON DISEASE; VIDEOTAPE RECORDING;

EID: 81555206409     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23893     Document Type: Article

References (14)

1. Kishore A, Espay AJ, Marras C, et al. Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: Differential effects on bradykinesia. Mov Disord. 2007; 22: 328-333.
2. Heldman DA, Giuffrida JP, Chen R, et al. The modified bradykinesia rating scale for Parkinson's disease: Reliability and comparison with kinematic measures. Mov Disord. 2011 [Epub ahead of print].
3. Kimber TE, Tsai CS, Semmler J, Brophy BP, Thompson PD. Voluntary movement after pallidotomy in severe Parkinson's disease. Mov Disord. 1999; 122: 895-906.
4. Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin Neuropharmacol. 2002; 25: 21-24.
5. Richard IH, Maughn A, Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Mov Disord. 1999; 14: 155-157.
6. Jiménez-Jiménez FJ, Tejeiro J, Martínez-Junquera G, Cabrera-Valdivia F, Alarcón J, García-Albea E. Parkinsonism exacerbated by paroxetine. Neurology. 1994; 44: 2406.
7. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996; 57: 449-454.
8. Lyons KE, Pahwa R. Deep brain stimulation in Parkinson's disease. Curr Neurol Neurosci Rep. 2004; 4: 290-295.
9. Perlmutter JS, Mink JW. Deep brain stimulation. Annu Rev Neurosci. 2006; 29: 229-257.
10. Papapetropoulos S, Jagid JR, Sengun C, Singer C, Gallo BV. Objective monitoring of tremor and bradykinesia during DBS surgery for Parkinson disease. Neurology. 2008; 70: 1244-1249.
11. Guo X, Gao G, Wang X, et al. Effects of bilateral deep brain stimulation of the subthalamic nucleus on olfactory function in Parkinson's disease patients. Stereotact Funct Neurosurg. 2008; 86: 237-244.
12. Espay AJ, Beaton DE, Morgante F, Gunraj CA, Lang AE, Chen R. Impairments of speed and amplitude of movement in Parkinson's disease: a pilot study. Mov Disord. 2009; 24: 1001-1008.
13. Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's disease. Adv Neurol. 1990; 53: 245-249.
14. Schwingenschuh P, Ruge D, Edwards MJ, et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord. 2010; 25: 560-569.